Introduction
Carcinoma cells recruit mesenchymal cells into the tumor-associated stroma; these mesenchymal cells then proceed to modify the stroma, helping to establish a tissue microenvironment that favors tumor progression. Paracrine signals emanating from the resulting tumor-associated stroma can subsequently modulate the behavior of the carcinoma cells (1) .
Among the recruited stromal cells are bone marrow-derived mesenchymal stem cells (MSCs), which are known to exhibit multipotent differentiation potential (2) . In the context of cancer pathogenesis, MSCs contribute to the formation of fibroblast and myofibroblast populations in the tumor-associated stroma (3, 4) and promote the growth, progression and metastasis of tumors (3, 5, 6) . Precisely how MSCs influence tumor progression is, however, poorly understood.
Elevated cyclo-oxygenase-2 (COX2) mRNA and protein levels are found in many malignant tissues and are often associated with poor clinical outcome (7) . The tumor-enhancing effects of COX2 are generally ascribed to its role in producing prostaglandin E2 (PGE 2 ), which has pleiotropic effects on cell proliferation, survival, angiogenesis, motility and invasiveness (8) . In addition to the neoplastic cells themselves, cells of the tumor-associated stroma contribute to elevated COX2 expression (9, 10) . However, it has been unclear whether the PGE 2 that promotes tumor progression derives from neoplastic cells, fibroblasts, macrophages, or some combination of these cell types.
Independent of these questions is the issue of heterogeneity of the neoplastic cells within carcinomas. Observations of a variety of human cancer types have revealed the existence of tumor-initiating cells (TICs), often called cancer stem cells (CSCs), which coexist as minority populations within tumors together with a majority population of cancer cells that lack tumor-initiating ability (11) . Passage by neoplastic epithelial cells through an epithelialmesenchymal transition (EMT) allows these cells to approach the stem-cell state (12, 13) . Moreover, EMT programs are known to be induced by heterotypic signals that epithelial cells receive from the microenvironment (14) . However, the nature of these heterotypic signals and the identities of the stromal cells that release them remain poorly understood.
We demonstrate here that, in response to stimulation by carcinoma cells, MSCs express greatly elevated levels of PGE 2 . The resulting PGE 2 , together with cytokines also induced in the MSCs, contribute to entrance of nearby carcinoma cells into a stem-cell-like state.
Results

PGE 2 induction in MSCs following interaction with carcinoma cells
We initially studied the interactions in culture of LoVo and SW1116 human colorectal carcinoma cells with MSCs. Minimal PGE 2 accumulation was observed in pure LoVo, SW1116 or MSC cultures monitored over a 72 h period ( Fig. 1Aa and Supplementary Fig.  S1A ). However, PGE 2 levels increased ~6.5 fold when the LoVo cells were cocultured with twice the number of MSCs for 48 h, and increased by ~60 fold after 72 h of coculture. Correspondingly, levels of the COX2 enzyme were also increased in the coculture (Fig.  1Ab ). In contrast, there was no PGE 2 increase in SW1116/MSC cocultures. Of note, PGE 2 production was induced equally strongly in [LoVo] [MSC] transwell cocultures, which only permitted their intercommunication via soluble factors ( Supplementary Fig. S1B ) and in MSCs treated with LoVo-conditioned medium (LoVoCM; Supplementary Fig. S1C and S1D). Hence, soluble factors secreted by LoVo cells were responsible for inducing PGE 2 production by MSCs.
Other work (in Supplemental Data, Section 1; Supplementary Figure S1E ) demonstrated that the secretion of IL-1 and IL-1 by carcinoma cell populations was correlated with their respective abilities to elicit PGE 2 production in co-cultured MSCs. Thus, when MSCs were treated with recombinant IL-1 or IL-1 , the induced PGE 2 levels were similar to or higher than those induced by LoVoCM (Fig. 1Ba) . Conversely, IL-1 -and IL-1 -neutralizing antibodies attenuated by 60% the production of LoVoCM-induced PGE 2 (Fig. 1Ba) . In addition, shRNAs directed against IL-1 and IL-1 mRNAs expressed in LoVo cells decreased by 84% the ability of their CM to induce PGE 2 in MSCs (Fig. 1Bb) and recombinant IL-1ra, a natural antagonist of the IL-1 receptor, attenuated by 73% the LoVoCM-induced PGE 2 production by MSCs (Fig. 1Bc) . IL-1 / secreted by the carcinoma cells was largely responsible for the PGE 2 production by MSCs, while IL-1ra could antagonize this induction.
Relationship of IL-1 production by carcinoma cells to their ability to induce PGE 2
The levels of the IL-1 , IL-1 and IL-1ra mRNAs and secreted proteins were quantified in six human breast carcinoma cell lines and the SW1116 colorectal carcinoma cell line, in addition to the LoVo cells examined above. Cells of the LoVo, HCC1806, BT549, SUM149 and SUM159 lines expressed elevated levels of IL-1 and/or IL-1 , but relatively low levels of IL-1ra; conversely, MDA-MB-453, MDA-MB-231 and SW1116 cells secreted little or no detectable IL-1 / and/or relatively high levels of IL-1ra ( Supplementary Fig. S1F and Fig.  1Ca ).
When cultured individually, the carcinoma cell lines expressed low or undetectable PGE 2 levels (Fig. 1Cb) . However, upon coculture with MSCs, the IL-1 / -secreting carcinoma cells induced ~80-500-fold increases of COX2 and PGE 2 production, while the carcinoma cells secreting low levels of IL-1 / failed to stimulate COX2 or PGE 2 formation (Supplementary Fig. S1G and Fig. 1Cb ). In addition, IL-1 -/IL-1 -neutralizing antibodies and IL-1ra attenuated PGE 2 production induced in MSCs by the conditioned media from the various IL-1-secreting carcinoma cells ( Supplementary Fig. S1H ). Hence, the ability to stimulate PGE 2 in MSCs appeared to be a frequent but not universal property of breast and colon carcinoma cells and was directly correlated with their abilities to signal via secreted IL-1 / . Because IL-1 and IL-1 were both capable of PGE 2 induction, we use the term "IL-1" to refer to both IL-1 and IL-1 in the text that follows.
Induction of cytokines in MSCs following their interaction with carcinoma cells
In addition to PGE 2 , GRO-, IL-6, IL-8 and RANTES in the culture media of LoVoMSC cocultures increased by 34, 10, 79 and 21 fold respectively following 120 h of coculture ( Fig. 2A) . In [LoVo] [MSC] transwell cultures, where direct contact between the LoVo cells and MSCs was prevented, PGE 2 , GRO-, IL-6 and IL-8 were induced to comparable levels; in contrast, RANTES expression was not elevated (Fig. 2A) . Following direct coculture, RANTES production occurred far more rapidly than did the accumulation of the other cytokines or PGE 2 ( Supplementary Fig. S2A ).
We also found that GRO-, IL-6 and IL-8, like PGE 2 , were induced by LoVoCM in MSCs ( Supplementary Fig. S1B ). To determine whether IL-1 was able, by itself, to induce concomitant production in MSCs of the three cytokines and PGE 2 , we assessed mRNAs levels in MSCs that had been treated for 48 h with vehicle or recombinant IL-1 (Fig. 2B) . The resulting 10-fold and 4-fold increases in MSCs of COX2 and mPGES1 (a second PGE 2 biosynthetic enzyme) mRNAs, the increase of COX-2 protein, and the 10~100-fold decrease of 15-PGDH mRNA (encoding the PGE 2 -degrading enzyme) confirmed the key role of IL-1 in modulating the levels of enzymes governing PGE 2 production and accumulation in MSCs. Moreover, IL-1 treatment alone elicited substantial increases (36-440 fold) of IL-6, IL-8 and GRO-mRNAs in MSCs. COX2, IL-6, IL-8 and GRO-mRNA induction was detectable within 30 minutes of IL-1 exposure and reached a maximum at 1-2 h thereafter ( Supplementary Fig. S2B ). This key role of IL-1 was further confirmed by knocking down IL1 / mRNAs in LoVo cells, resulting in a 60-90% decrease in the induced levels of IL-6, IL-8 and GRO-mRNAs ( Supplementary Fig. S2C ). Thus, IL-1 was both necessary and sufficient to induce PGE 2 , IL-6, IL-8 and GRO-production in MSCs.
We also confirmed that LoVoCM and IL-1 could induce comparable levels of PGE 2 ( Supplementary Fig. S2D ) and cytokine ( Supplementary Fig. S2E ) in other types of mesenchymal cells that may arise from the differentiation of MSCs (4), including human breast mesenchymal stem cells (bMSCs) isolated from a breast cancer patient, human colonic myofibroblasts (CCD-18co), and primary human mammary stromal fibroblasts.
Autocrine PGE 2 cooperation with IL-1 paracrine signaling leading to PGE 2 and cytokine production by MSCs IL-8 and IL-6 are known to be induced in certain cells by PGE 2 (15) . To determine whether PGE 2 played a role in the induction of these cytokines in MSCs, PGE 2 production by MSCs was blocked with indomethacin, which inhibits the COX1 and COX2 enzymes. In LoVo/ MSC cocultures, GRO-, IL-6 and IL-8 protein induction was reduced by 85-98% by indomethacin; moreover this induction could be partially rescued by providing PGE 2 to indomethacin-treated cocultures (Fig. 2C) . While PGE 2 treatment alone could not induce GRO-, IL-6 or IL-8 expression in LoVo cells or MSC cells, additional PGE 2 potentiated the cytokine induction in LoVo/MSC cocultures and in IL-1-treated MSCs ( Fig. 2C and Supplementary Fig. S2F ).
MSCs expressed two distinct PGE 2 cell-surface receptors, EP2 and EP4 ( Supplementary  Fig. S2G ). To support the notion that MSC-derived PGE 2 acted in an autocrine fashion, the EP2 and EP4 receptor antagonists AH6809 and GW627368X were added to MSC cultures, along with either LoVoCM or IL-1. LoVoCM-and IL-1-induced IL-6, IL-8 and GROmRNA was suppressed by 60-80% by these EP receptor antagonists (Fig. 2D) . Figure 2E summarized our model that (i) COX2, mPGES1 and PGE 2 are initially induced in MSCs by IL-1 released by carcinoma cells and that (ii) the resulting PGE 2 , acting in an autocrine manner on MSCs, then cooperates with ongoing IL-1 paracrine signaling to trigger IL-6, IL-8 and GRO-production by MSCs (Fig. 2E) .
Effects of MSCs on carcinoma cell mesenchymal and invasive traits
Before further analyzing the interactions between the carcinoma cells and MSCs, we confirmed that, as reported by others (5, 16) , MSCs are indeed recruited to IL-1-secreting tumors in vivo (described in Supplemental Data, Section 2; Supplementary Fig. S3A-B) .
Having done so, we further investigated the influence of MSCs on carcinoma cell behavior, more specifically by analyzing the effects of MSC coculture on the expression by the tumor cells of markers of EMT, a cell-biological program that imparts motility, invasiveness, and self-renewal to carcinoma cells (14) . After culturing, either alone or together with tdTomatoMSCs (5 days), LoVo and HCC1806 cells were isolated by FACS and analyzed for Ecadherin, vimentin, fibronectin and -actin protein expression (Fig. 3A) . E-cadherin, the key epithelial marker, was decreased by 98-100% in both LoVo and HCC1806 cells cocultured with MSCs. Conversely, vimentin and fibronectin proteins -both mesenchymal markerswere robustly induced in both carcinoma cells (Fig. 3A) . Moreover, expression of the Snail protein, an EMT-inducing transcription factor (EMT-TF), was increased 5-69 fold in the MSC:carcinoma cocultures (Fig. 3A) .
We then determined whether PGE 2 and/or the cytokines produced by MSCs in LoVo/MSC cocultures could elicit an EMT-like response in LoVo cells. PGE 2 was able, on its own, to cause a decrease in E-cadherin protein in LoVo cells (Fig. 3B , ~70% decrease) but failed to elicit concomitant robust increases of mesenchymal markers, i.e., vimentin, and the Zeb1, Snail and Twist1 EMT-TFs (Fig. 3B ).
In contrast to PGE 2 , IL-6 alone induced Zeb1 (7 fold), Snail (3 fold), and vimentin (3 fold) protein expression in LoVo cells, but was unable to decrease E-cadherin protein. However, treatment of LoVo cells with PGE 2 together with the four cytokines induced both a decrease of E-cadherin protein expression (~80%) and increases of vimentin (9 fold), Zeb1 (14 fold), Snail (13 fold) and Twist1 (10 fold) protein expression (Fig. 3B) . Hence, activation of a more complete EMT program in the carcinoma cells required the concomitant activation of multiple signaling pathways, specifically those triggered in these cells by PGE 2 acting together with the indicated cytokines.
Significantly more carcinoma cells invaded in LoVo/MSC cultures than in cultures of LoVo cells alone (Fig. 3C ). To examine whether PGE 2 played a critical role in the MSC-induced carcinoma cell invasiveness, LoVo/MSC cocultures were treated with NS398, a COX2 inhibitor; this treatment resulted in an 80% reduction of MSC-induced LoVo cell invasiveness (Fig. 3C ). Greater than 60% of this inhibition could be reversed by adding PGE 2 to these cocultures. Also, LoVo cell invasion was significantly reduced by antibodies that neutralize either IL-6, GRO-or RANTES (Fig. 3D) . Accordingly, the MSC-induced carcinoma cell invasiveness appeared to derive from a confluence of PGE 2 , IL-6, GRO-and RANTES signals impinging on the LoVo cells.
We also examined possible effects of MSCs on carcinoma cell invasion in vivo. The carcinoma cells injected on their own formed reasonably well-encapsulated tumors (Fig. 3E , a, b, c). In contrast, the carcinoma cells co-injected with MSCs formed extensive invasive fronts that extended into adjacent muscle layers (Fig. 3E, d , e, f). In addition, we observed the intravasation of carcinoma cells into nearby microvessels (Fig. 3E , insert). To summarize, these data indicated that MSCs facilitated LoVo cell invasion both in vitro and in vivo.
Effects of MSCs on tumor initiation by carcinoma cells
Since transformed epithelial cells that have undergone EMT contain larger subpopulations of TICs (12, 13, 17) , we determined whether EMT induction of carcinoma cells by MSCs was similarly accompanied by an increase in tumor-initiating ability. When populations of 5 × 10 4 IL-1-secreting carcinoma cells were co-injected with 2 × 10 5 MSCs, their ability to give rise to palpable tumors was measurably increased (1/6 to 6/6 for LoVo, 1/6 to 6/6 for HCC1806, 0/6 to 5/6 for SUM159 and 1/6 to 5/6 for SUM149, Fig. 3F ). In contrast, tumor initiation by 5 × 10 4 MDA-MB-231 or MDA-MB-453 cells, neither of which secrete IL-1, was not increased by co-injection with 2 × 10 5 MSCs.
We quantified these interactions more precisely by implanting limiting dilutions of LoVo cells at four dosages, together with 5 × 10 5 admixed MSCs. The presence of admixed MSCs increased the tumor-initiating frequencies of 5 × 10 5 , 5 × 10 4 and 5 × 10 3 implanted LoVo cells from 4/6, 1/6 and 0/6 to 6/6, 6/6 and 6/6. (Fig. 3G) . As judged by the ELDA (Extreme limiting dilution analysis) (18) , the frequency of TICs in cultured LoVo cells was 9 × 10 −7 -6 × 10 −5 ; in the presence of admixed MSCs this frequency increased to 1 × 10 −3 -1 × 10 −2 ( Fig. 3H ).
MSC-induced increases in ALDH high CSC-enriched population and tumor initiation
CSCs, which have some characteristics associated with normal stem cells, are cells defined operationally by their tumor-initiating ability (19) . We validated the use of aldehyde dehydrogenase as a marker of tumor-initiating cells and thus CSCs (20, 21) (described in Supplemental Data, Section 3; Supplementary Fig. S4A-C and S5A-B) . We observed that a 5-day coculture of LoVo or HCC1806 cells with MSCs resulted in ~7-fold and ~20-fold increases, respectively, in ALDH1 protein levels in the carcinoma cells ( Fig. 4A and Supplementary Fig. S5C ). To extend this observation, we cultured an unfractionated LoVo cell population or already-sorted ALDH high or ALDH low LoVo cell subpopulations ( Supplementary Fig. S4Ba) , either alone or in the presence of a two-fold excess of tdTomato-labeled MSCs, for 5 days. All three LoVo cell populations, when cocultured with MSCs, developed larger subpopulations of ALDH high cells (59%, 38% and 18%) than when cultured alone (38%, 20% and 7%), i.e., 1.6-to 2.6-fold increases in ALDH high cells (Fig.  4Ba) .
We also used FACS to remove the tdTomato-MSCs from LoVoMSC cocultures, then further propagated the LoVo cells for 5 days in the absence of MSCs. We found that the levels of the ALDH high LoVo cell subpopulations that had previously been increased by coculture with MSCs reverted to levels comparable to those observed in LoVo cells that had never experienced MSC coculture (Fig. 4Bb) . Our data indicated that maintenance of elevated numbers of ALDH high LoVo cells depended on continuous interactions of the LoVo cells with MSCs.
Use of the ALDH marker as the sole stem-cell marker is likely to have led to an underestimate in the increase of the number of CSCs, since ALDH high cells are a CSCenriched population rather than being a pure CSC population. In order to refine the markers used to identify CSCs, we determined that a LoVo subpopulation more enriched for CSCs could be identified by concomitant use of the ALDH high and CD133 + markers, which have been used to define CSCs in various cancer cell populations (22-25) (described in Section 3, Supplemental Data; Supplementary Fig. S6A-C) . Indeed, in the LoVo cells cocultured for five days with MSCs, the ALDH high /CD133 + LoVo cells were increased from 1.4% to 16.4% of the overall cell population, i.e., a 11.7-fold increase ( Supplementary Fig. S6C ).
We also determined whether the MSC-induced increase of ALDH high LoVo cells observed in culture was accompanied by an increase of TICs in LoVo cells. Limiting dilutions of sorted ALDH high and ALDH low LoVo cells were injected subcutaneously into SCID mice, either alone or together with MSCs (Fig. 4Ca) . As calculated using ELDA, the TIC frequency of ALDH high LoVo cells injected on their own was 4 × 10 −5 -3 × 10 −4 , while that of ALDH high LoVo coinjected with MSCs was 2 × 10 −3 -1 (Fig. 4Cb) . For ALDH low LoVo cells injected alone, the TIC frequency was 7 × 10 −7 -5 × 10 −6 ; co-injection with MSCs increased this frequency to 3 × 10 −4 -2 × 10 −3 (Fig. 4Cb) . TIC frequencies of both ALDH high and ALDH low LoVo cells were increased by several orders-of-magnitude when co-injected with MSCs.
The continued presence of MSCs in the implanted cell populations complicates interpretation of the direct effects of MSC on the tumor initiation of carcinoma cells, since the MSCs might affect tumor initiation by a number of different mechanisms. To address this issue, LoVo cells or HCC1806 cells were isolated by FACS from 5-day carcinoma cell/ tdTomato-MSC cocultures and were then immediately injected subcutaneously into SCID mice, in parallel with LoVo cells previously cultured alone, in order to determine the effect on the tumor initiation of the cell culture interactions ( Fig. 4D and Supplementary Fig.  S7A ). Accordingly, TIC frequencies of LoVo cells were increased by one order-ofmagnitude following 5-day co-culture with MSCs in vitro (Supplementary Fig. S7B ). An increase of tumor initiation by prior co-culture with MSCs was also observed on HCC1806 cells (Supplementary Fig. S7C ).
Influence of PGE 2 signaling on the ALDH high CSC state
To understand more precisely how the signals exchanged between carcinoma cells and MSCs led to increases in ALDH high CSCs, we first ascertained whether PGE 2 and/or cytokines produced by MSCs in LoVo/MSC cocultures could elicit ALDH1 expression. Only PGE 2 was able, on its own, to elicit an increase in ALDH1 expression in LoVo cells (Fig. 5A) . Moreover, when PGE 2 was combined with the four cytokines there was no further increase in ALDH1 expression.
EP4 is the only PGE 2 receptor highly expressed by LoVo cells (Supplementary Fig. S2G ). To elucidate in more depth the effects of PGE 2 on LoVo cells, we treated these cells with vehicle or PGE 2 for 5 days. The vehicle-treated cultures contained 10.3% ALDH high LoVo cells, while the LoVo cells treated with PGE 2 contained ~25% ALDH high LoVo cells (Fig.  5B) . We added GW627368X (the EP4 receptor antagonist) to LoVo cells to determine whether the basal, unperturbed levels of ALDH high cells depended on ongoing PGE 2 autocrine signaling; this treatment reduced by ~60% the basal level of ALDH high LoVo cells (Fig. 5B) . These data suggested that within LoVo cells, subpopulations of cells are maintained in an ALDH high state in part through ongoing, low-level autocrine PGE 2 signaling. Moreover, this signaling and associated entrance into the ALDH high state could be enhanced by exogenously supplied PGE 2 .
The observed increase in ALDH1 expression induced by PGE 2 was not confined to LoVo cells. PGE 2 treatment induced elevated ALDH1 expression (2.9 -12.9 fold) in LoVo, SUM149, SUM159 and BT549 cells (Fig. 5C ), all of which were previously found to elicit increased PGE 2 production from cocultured MSCs.
The LoVo cells that had been treated ex vivo with vehicle or PGE 2 for 5 days were implanted subcutaneously in SCID mice. Tumors derived from control LoVo cells occurred in 3 of 16 injected hosts, while the corresponding PGE 2 -treated cells formed tumors in 18 of 24 hosts (Fig. 5D ). Hence, a substantial increase in ALDH high cells and TICs could be achieved by PGE 2 treatment of LoVo cells ex vivo. Moreover, treating LoVo cells with the cocktail of cytokines (IL-6, IL-8, Gro-and RANTES) in addition to PGE 2 did not significantly increase the tumor initiation beyond that observed for PGE 2 treatment alone ( Supplementary Fig. S8 ). In addition to its effects on TICs, PGE 2 is likely to contribute to the maintenance of CSCs in vivo by increasing tumor angiogenesis ( Supplementary Fig. S9 , discussed in Supplemental Data, section 4).
Role of PGE 2 signaling in the MSC-induced ALDH high CSC-enriched population and tumor initiation
To confirm that the above-described role of PGE 2 could explain the ability of MSCs to induce CSC formation, we inhibited PGE 2 synthesis with NS398, or PGE 2 signaling with GW627368X, in cocultures of LoVo cells and tdTomato-MSCs. Blocking PGE 2 signaling by either route prevented most of the increases in ALDH high LoVo CSCs by MSCs (described in Section 5, Supplemental Data; Supplementary Fig. S10 ). LoVo cells that had been cocultured under the various conditions with MSCs for 5 days were sorted by FACS to eliminate tdTomato-MSCs and were then injected subcutaneously into SCID mice. The increase in TIC frequencies resulting from a 5-day coculture with MSCs (from 4/20 to 14/19) was prevented by introducing either NS398 or GW627368X into the cocultures (from 14/19 to 3/17 or 1/12, respectively, Fig. 5E ). Adding PGE 2 to the cocultures along with NS398 restored the tumor-initiating frequency from 3/17 to 7/8.
To validate the role of COX2 in these properties, we knocked down COX2 in MSCs. The ability of the resulting MSCshcox-2 cells to produce PGE 2 in response to LoVoCM was reduced by 90% (Fig. 5Fa) . The tumor-initiating frequency of 5 × 10 4 LoVo cells was increased from 1/12 to 10/12 by co-injection with MSCs expressing a control, scrambled shRNA (MSCshsc cells; Fig. 5Fb ). In contrast, in mice co-injected with MSCshcox2 cells, the tumor-initiating frequency of LoVo cells was increased from 1/12 to only 3/12, supporting the notion that COX2-dependent PGE 2 induced in MSCs was required for the observed robust increases of LoVo TICs.
PGE 2 induces β-catenin nuclear localization and transactivation
The -catenin signaling pathway has been implicated in maintaining stem cell and CSC homeostasis in most epithelial tissues (26, 27) . Relevant here is the finding that PGE 2 treatment leads to Akt activation; activated Akt subsequently stimulates -catenin signaling in several ways (28, 29) . Accordingly, we examined activation of Akt/GSK-3/ -catenin signaling axis in LoVo cells treated with vehicle, PGE 2 , GW627368X, or GW627368X + PGE 2 . We found that PGE 2 treatment led to a 12-fold increase in Akt phosphorylation at Thr473 (Fig. 6A) , which indicates functional Akt activation (30) . Conversely, inhibiting PGE 2 signaling with GW627368X in PGE 2 -treated LoVo cells blocked 50% of the PGE 2 -induced Akt phosphorylation (Fig. 6A) . Moreover, -catenin activity is positively affected by Akt-mediated phosphorylation of its Ser552 residue (31, 32) . PGE 2 treatment of LoVo cells, which caused a 12-fold increase of Akt phosphorylation, also increased -catenin phosphorylation at Ser552 (11 fold), an increase that was blocked entirely by GW627368X treatment (Fig. 6A) .
Akt also enhances -catenin by phosphorylating and thereby inactivating glycogen synthase kinase-3 (GSK3); this prevents inactivation of -catenin by unphosphorylated GSK3, since Ser21-unphosphorylated GSK-3 and Ser9-unphosphorylated GSK-3 phosphorylatecatenin at its Ser33/Ser37/Thr41 residues, leading to its degradation (33, 34) . PGE 2 strongly increased the phosphorylation of GSK-3 at Ser21 (56 fold above basal level, Fig. 6A ). Although Ser9 of GSK-3 was already phosphorylated prior to PGE 2 treatment, this basal level of GSK-3 Ser9 phosphorylation was reduced (70%) by adding GW627368X (Fig.  6A) , presumably by blocking basal autocrine PGE 2 signaling. Inhibition of PGE 2 signaling by GW627368X prevented the inactivating phosphorylation of GSK-3 and GSK-3 and, conversely, increased phosphorylation of -catenin at Ser33/Ser37/Thr41 residues 15 fold that lead to its degradation (Fig. 6A ). These data indicated that inhibition of PGE 2 signaling leads to -catenin phosphorylation, a prelude to its proteasomal degradation.
A strong inhibition of -catenin signaling is also achieved by E-cadherin, which recruitscatenin to adherens junctions associated with the plasma membrane, thereby preventing its nuclear localization and its actions in promoting transcription (35) . PGE 2 decreased the Ecadherin and ZO-1 protein located at the cell junctions ( Fig. 6B and 6C ). Correspondingly, in PGE 2 -treated LoVo cells -catenin was found in cell nuclei, rather than being sequestered by E-cadherin in adherens junctions, (Fig. 6B and 6C) . PGE 2 caused a 5.3-fold increase of -catenin in the nuclear fraction; this increase was blocked by adding the EP4 antagonist during PGE 2 treatment (Fig. 6D) . We also found, by analyzing expression in LoVo carcinoma cells of a number of -catenin/TCF-regulated genes, that PGE 2 -induced nuclear -catenin was functionally active (Fig. 6E) .
PGE 2 -induced effects on ALDH high cancer cells are mediated by β-catenin signaling
PGE 2 induces Akt phosphorylation in carcinoma cells in a phosphatidylinositol 3-kinase (PI3K)-dependent manner (28) . To determine if the activation of the Akt/GSK-3/ -catenin signaling axis was required for PGE 2 -induced ALDH high LoVo CSCs, we treated ALDH high LoVo cells with vehicle, PGE 2 , GW627368X, LY294002 (a PI3K inhibitor), FH353 (acatenin/TCF inhibitor), or cardamonin (a -catenin inhibitor) for 5 days at concentrations that did not cause significant cell death.
LY294002 functioned as efficiently as the EP4 antagonist by completely blocking the exogenous PGE 2 -induced increase of ALDH high LoVo cells and by decreasing the endogenous PGE 2 -maintained basal ALDH high LoVo cells (Fig. 6F, a and d) . Although the two -catenin inhibitors, FH353 and cardamonin, blocked the PGE 2 -induced increase of ALDH high LoVo cells ( Fig. 6Fb and 6Fc ), these inhibitors did not function as effectively as the EP4 antagonist or the PI3K inhibitor. PGE 2 /EP4 signaling, acting through the Akt/ GSK-3/ -catenin signaling axis (28) , contributes to induction of the ALDH high LoVo cell phenotype.
Contribution of MSCs in tumor stroma to the stem-cell niche of ALDH high CSCs
PGE 2 is metabolically unstable and is thought to act within tissues over short distances, doing so in both an autocrine and a paracrine manner. Wishing to pursue this notion further, we examined whether ALDH high CSCs were located near MSCs (or their mesenchymal derivatives) in tumors that arose following the coinjection of these two cell types. ALDH high LoVo cells (Fig. 7Aa, red signal) were often surrounded by tdTomato-labeled MSCs (Fig.  7Aa, green signal) or their derivatives in tissue sections of LoVo/MSC xenografts; in addition, many of these mesenchymal cells expressed COX2 (Fig.7Aa, cyan signal) . Moreover, the mesenchymal cells associated with the ALDH high tumor cells expressed FSP, the fibroblast marker (Fig 7Ab, red signal ; discussed in Supplemental Data, section 6; Supplementary Fig. S11 ), indicating that the MSC-derived fibroblasts rather than their MSC precursors were largely responsible for forming the stromal microenvironment of these ALDH high cells. The conclusion that PGE 2 induces the formation of ALDH high CSCs was further supported by human colorectal adenocarcinoma studies in which we found the juxtaposition within tumors of such CSCs with stroma expressing COX2, the likely source of PGE 2 production (discussed in Supplemental Data, section 7; Supplementary Fig. S12A -B). These observations lead us to propose that MSCs (or their differentiated derivatives) create a niche within tumors, leading to induction and/or maintenance of CSC subpopulations.
Correlation of COX2 expression with CSC properties and a more aggressive tumor phenotype
To determine whether elevated IL-1 production correlates with COX2/PGE 2 expression in human primary carcinomas, we compared the normalized IL-1 , IL-1 and COX2 mRNA levels across 19 human normal colon and 123 human colon carcinoma samples and across 178 human invasive breast carcinoma samples [Cancer Genome Atlas analyzed by Oncomine™]. IL-1 and IL-1 were expressed at significantly higher levels (9.6 fold and 4.7 fold in colon carcinoma and 2.1 fold and 2.1 fold in breast carcinoma) in aggressive subtypes of samples ---colon mucinous carcinoma and Triple-negative breast carcinoma (TNBC) respectively (Fig. 7B) . Moreover, the COX2 mRNA levels were correlated with the IL-1 and IL-1 mRNA levels; COX2 mRNA was elevated 5.4 fold and 5.3 fold in colon mucinous carcinoma and TNBC when compared to normal colon samples and other breast cancers (Fig. 7B ). These correlations suggested that the signaling mechanisms described above (Fig. 7C) , involving IL-1 activated expression of COX2/PGE 2 , may be relevant to understanding the pathogenesis of colon mucinous carcinomas and TNBCs.
Discussion
Elevated IL-1 expression has been correlated with increased malignant progression and more aggressive phenotypes in many types of cancer (36) . However, the mechanism(s) underlying this correlation have been unclear. We describe here a bidirectional, reciprocal interaction between carcinoma cells and the MSCs (Fig. 7C) . The signaling is initiated through the release of IL-1 by carcinoma cells. We present evidence that appears to explain this connection between IL-1 production and increased tumor aggressiveness in many, and perhaps all IL-1-secreting carcinomas.
IL-1 secreted by carcinoma cells induces COX2 and mPGES1 expression in MSCs. The two enzymes collaborate in MSCs to generate PGE 2 levels, which can increase by 80 to 500 fold (Fig. 1Cb) . Of note, we show these responses operate equally well in MSCs and in their more differentiated descendants ( Supplementary Fig. S2D and S2E ). We note that others recently reported that IL-1 secreted by head-and-neck squamous cell carcinoma cells induce PGE 2 from fibroblasts (37). Consequently, fibroblasts and myofibroblasts, both of which accumulate in large numbers in the stroma, may also represent sources of the PGE 2 and the subsequently produced cytokines described here.
Importantly, while COX2 is highly expressed in both neoplastic and stromal cells in tumors, not all COX2-expressing cells can produce PGE 2 . Thus, despite large variations in COX2 expression, the colorectal carcinoma cell lines that we examined produced only about 10-40 pg/ml of PGE 2 ( Supplementary Fig. S1A ). These levels are dwarfed by the 15,000-40,000 pg/ml of produced by the IL-1-stimulated MSCs studied here (Fig. 1Cb) . This failure by COX2-expressing carcinoma cells to produce significant levels of PGE 2 may be due to the absence in many carcinoma cells of significant levels of mPGES1 expression ( Supplementary Fig. S1A and S1D) . Hence, COX2 expression, on its own, is unlikely to provide an accurate indication of PGE 2 production by carcinomas.
MSC-produced PGE 2 acts in two ways within such tumors -in an autocrine fashion on the MSCs that produced it and in a paracrine fashion on the nearby IL-1-releasing carcinoma cells. The MSC autocrine signaling elicits a second wave of signaling responses: In collaboration with ongoing paracrine IL-1 signaling from carcinoma cells, the autocrine PGE 2 induces IL-6, IL-8, GRO-and RANTES cytokines in the MSCs. Together, these MSC-derived molecules induce a third wave of responses that profoundly alter the carcinoma cells that initiated this signaling cascade ( Fig. 2E and 7C ).
The changes induced in carcinoma cells by the confluence of PGE 2 and cytokine signals are all components of the complex cell-biological program termed the EMT. While this program has been increasingly implicated in the acquisition of phenotypes associated with high-grade malignancy (14) , major questions concerning the EMT have remained unanswered. Among them are the paracrine signals, ostensibly of stromal origin, that trigger the EMT in carcinoma cells. Here we present a scenario that explains how the EMT can be induced in carcinoma cells by a reactive stroma.
The present work also addresses another longstanding puzzle concerning the EMT: Is it usually activated as a single, coherent program or, alternatively, are distinct components of this program activated separately, each by a distinct set of heterotypic signals? Our observations indicate that the latter scenario is more likely. For example, PGE 2 caused a decrease of E-cadherin expression in carcinoma cells, while cytokines were required to induce the vimentin and ZEB1 expression that is usually depicted as intrinsic components of EMT program (Fig. 3B) . Such responses suggest the possibility that, during the course of spontaneous tumor progression, some carcinoma cells may receive only a subset of these signals and accordingly only activate portions of the EMT program, while others receiving the complete suite of heterotypic signaling molecules may pass through an entire EMT program.
Research by ourselves and others has connected EMT with entrance into a stem-cell like state, both in normal and neoplastic epithelial cells (12, 13, 17) . These findings are also echoed by the present work, in which we observe a concomitant entrance into the mesenchymal and stem-cell states in response to MSC-derived heterotypic signals. PGE 2 , which activated portions of the EMT program, was able to increase both the number of CSCs and the frequency of tumor initiation (Fig. 5A-5D ). Our findings here further clarify the connection of EMT with entrance into a stem-cell like state by showing that the partial EMT induced by PGE 2 , which represses cell-cell junctions without inducing mesenchymal traits, suffices to increase CSCs. The observation of MSC-induced increases in CSCs is consistent with the recent finding of prostaglandin-induced increases in the number of CD44+ tumor cells (38, 39) . The unique contribution of PGE 2 is underscored by the observation that other MSC-derived cytokines, when combined with PGE 2 , had only marginal effects on further increasing the TIC frequency ( Supplementary Fig. S8 ).
In earlier work (27) In tumors that arise from IL-1-producing carcinoma cells, we find that this interleukin plays a critical role in the tumor cell-induced COX2/mPGES1/PGDH/PGE 2 response in MSCs that is required for tumor progression. IL-1 blockage has been used in thousands of patients to control infection and inflammatory disease and has a remarkable safety record (40) . Based on our findings and the existing clinical use of IL-1 inhibitors, IL-1 inhibition may present a promising alternative to COX2 inhibitors for cancer therapy. In addition, limited therapeutic options are currently available for TNBCs, which produce higher levels of IL-1 (Fig. 7B ), because they are unresponsive to standard receptor-mediated treatments. Accordingly, our findings suggest a possible option for treating these aggressive subtypes of breast and colon cancer.
Materials and Methods
Cell Culture
Human carcinoma cell lines HCC1806, BT549, MDA-MB-231, -453, SW1116 and LoVo were obtained from ATCC and human bone-marrow derived MSC (Sciencell) were obtained from Sciencell. SUM149 and SUM159 cells were provided by SP Ethier (Wayne State University). The human carcinoma cell lines SUM149, SUM159, BT549, MDA-MB-231, -453, SW1116 and LoVo were authenticated by microarray analysis. HCC1806 and MSC were not passaged more than 6 months after receipt.
Animal experiments
All research involving animals complied with protocols approved by the MIT Committee on Animal Care. In experiments evaluating tumor initiation and growth, the tumors were isolated and weighed at the end of each experiment. To measure TIC frequency, serial dilutions of cancer cell suspensions were injected subcutaneously into nude mice. TIC frequencies of the samples were determined using the ELDA web tool at http:// bioinf.wehi.edu.au/software/elda.
ALDH activity assay
ALDH activities of the carcinoma cells were measured with the ALDEFLUOR® fluorescent reagent system (STEMCELL Technologies), according to the manufacturer's protocol.
Significance
While prostaglandin E 2 has been implicated time and again in fostering tumorigenesis, its effects on carcinoma cells that contribute specifically to tumor formation are poorly understood. Here we show that tumor cells are able to elicit a strong induction of the COX2/mPGES1/PGE 2 axis in mesenchymal stem cells recruited to the tumor-associated stroma by releasing IL-1, which in turn elicits a mesenchymal/stem-cell-like phenotype in the carcinoma cells. 
